Machine Learning Algorithms for Predicting Urinary Tract Infections: Integration of Demographic Data and Dipstick Reflectance Results

Clin Chem. 2025 Aug 26:hvaf088. doi: 10.1093/clinchem/hvaf088. Online ahead of print. ABSTRACT BACKGROUND: Urinary tract infections (UTIs) are among the most common infections encountered in healthcare settings. Current diagnostic practices often require 24-48 h due to the time needed for culture results. Given that 70%-80% of cultures return negative, there is significant interest in rapidly … Read more

In Vitro Metabolic Profiling of 18 Semi-Synthetic Cannabinoids-Hexahydrocannabinol (HHC) and Its Analogs-with Identification in an Authentic Hexahydrocannabiphorol (HHCP) Urine Sample

Clin Chem. 2025 Aug 25:hvaf087. doi: 10.1093/clinchem/hvaf087. Online ahead of print. ABSTRACT BACKGROUND: Hexahydrocannabinol (HHC) and its analogs are recent additions to semi-synthetic cannabinoids in the recreational drug market. Here, the metabolism of 18 HHC analogs was compared to gain a comprehensive understanding of the structure-metabolism relationship of HHC analogs and to identify urinary biomarkers. … Read more

Post-Translationally Modified Proteoforms as Biomarkers: From Discovery to Clinical Use

Clin Chem. 2025 Aug 25:hvaf094. doi: 10.1093/clinchem/hvaf094. Online ahead of print. ABSTRACT BACKGROUND: Protein biomarkers are routinely measured for disease diagnosis and prognosis in clinical laboratories. Since most assays focus on protein quantity, information about proteoforms is often not acquired. Proteoforms of a protein represent the complex integration of genetic polymorphism, alternative splicing of RNA … Read more

A Parametric Empirical Bayes Approach to Personalized Reference Intervals and Reference Change Values

Clin Chem. 2025 Aug 22:hvaf092. doi: 10.1093/clinchem/hvaf092. Online ahead of print. ABSTRACT BACKGROUND: Population-wide reference intervals (RIpop) are commonly used in laboratory medicine but may not reflect an individual’s tightly regulated homeostatic interval. Personalized reference intervals (RIper) could enhance diagnostic precision by accounting for individual variability. A parametric empirical Bayes (PEB) framework stabilizes individual estimates … Read more

Interdisciplinary Collaboration to Develop a Custom Genomic Analysis Pipeline for the Clinical Laboratory: Hepatitis B Virus and Cytomegalovirus Antiviral Resistance Genotyping

Clin Chem. 2025 Aug 21:hvaf093. doi: 10.1093/clinchem/hvaf093. Online ahead of print. ABSTRACT BACKGROUND: Next-generation sequencing for hepatitis B virus (HBV) and cytomegalovirus (CMV) antiviral drug resistance (AVDR) testing improves the sensitivity of variant detection, but availability of bioinformatics and analytical pipelines are key barriers to implementation. METHODS: Plasma was extracted on MagNA Pure 24 (Roche … Read more

Urine Cell-Free RNA vs Plasma Cell-Free RNA for Monitoring of Kidney Injury and Immune Complications

Clin Chem. 2025 Aug 12:hvaf082. doi: 10.1093/clinchem/hvaf082. Online ahead of print. ABSTRACT BACKGROUND: There is increasing interest in the use of circulating cell-free RNA (cfRNA) in plasma as an analyte for diagnosing and monitoring disease. While it is known that cfRNA can also be isolated from urine, the diagnostic potential of urine cfRNA, particularly relative … Read more

Allelic Cataloging of RHD-RHCE Reference Sequences Using Targeted Long-Read Sequencing

Clin Chem. 2025 Aug 8:hvaf090. doi: 10.1093/clinchem/hvaf090. Online ahead of print. ABSTRACT BACKGROUND: Implementation of blood group genotyping has offered substantial benefits in transfusion medicine. However, the complex molecular basis of Rh antigen expression and a high degree of sequence homology between RHD and RHCE have long limited the accuracy of blood group genotyping, highlighting … Read more

Gene Therapy for Hemophilias: Opportunities and Challenges for the Clinical Laboratory

Clin Chem. 2025 Aug 7:hvaf085. doi: 10.1093/clinchem/hvaf085. Online ahead of print. ABSTRACT BACKGROUND: Hemophilia A and B are X-linked coagulation disorders characterized by low or dysfunctional Factor VIII (FVIII) or IX (FIX), respectively. Currently, hemophilia A and B are treated by FVIII/FIX replacement therapy with plasma-derived or recombinant products or by FVIII-mimetic agents (e.g., emicizumab). … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri